Navigating Keytruda Prior Authorization for Orthopedics

Keytruda's Role in Orthopedic Oncology Pathways

While Keytruda (pembrolizumab) is primarily an oncology immunotherapy, its application extends to specific bone and soft tissue sarcomas, which often fall under the purview of orthopedic oncology. For indications like advanced or recurrent soft tissue sarcoma, Keytruda may be utilized, frequently guided by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). This necessitates orthopedic practices to navigate complex oncology-specific prior authorization criteria.

Key Documentation for Keytruda Prior Authorization in Orthopedic Oncology

• Pathology reports confirming diagnosis and tumor characteristics, including relevant biomarker testing (e.g., MSI-H/dMMR status for specific indications).
• Detailed imaging reports (MRI, CT, PET) demonstrating tumor burden, location, and response to prior therapies, critical for surgical planning.
• Documentation of prior systemic therapies, including dates, agents, and patient response, to demonstrate adherence to step-therapy requirements.
• Patient performance status (e.g., ECOG or Karnofsky) and a comprehensive medical history to support treatment appropriateness.
• Multidisciplinary care team notes, including surgical oncology, medical oncology, and radiation oncology, outlining the comprehensive treatment plan.
• Evidence of progression on prior lines of therapy, or specific genetic mutations/biomarkers as per NCCN guidelines.

Addressing Common Prior Authorization Denials for Keytruda in Orthopedics

Denials for Keytruda in orthopedic oncology often stem from a confluence of oncology-specific and general PA challenges. These can include insufficient documentation of prior lines of therapy, lack of specific biomarker testing results (e.g., MSI-H/dMMR) where required, or the absence of clear correlation between imaging findings and clinical progression. Additionally, general orthopedic PA issues like inadequate conservative care trial documentation (though less common for Keytruda itself, but relevant to the overall patient journey) or site-of-service mismatches can complicate the broader treatment plan.

Workflow Optimization for Orthopedic Oncology Prior Authorizations

• Orchestrating multi-disciplinary PA pathways, integrating requirements from medical oncology, surgical oncology, and radiation oncology.
• Managing the sequencing of imaging, surgical planning, and systemic therapy PAs to align with critical pre-operative scheduling windows.
• Automating the extraction of critical data points from EMRs, including pathology reports, genetic test results, and imaging studies.
• Facilitating efficient peer-to-peer review scheduling for complex cases where clinical necessity is challenged, often involving both oncology and surgical expertise.
• Ensuring documentation of adherence to NCCN Guidelines to support medical necessity for payer review.

Klivira's Solution for Keytruda Prior Authorization in Orthopedic Oncology

Klivira's platform is engineered to automate the intricate prior authorization process for high-value treatments like Keytruda within orthopedic oncology. By leveraging SMART on FHIR integration with your EMR, Klivira can automatically identify and extract critical patient data—from pathology reports and genetic testing results to imaging studies and prior treatment histories. Our system orchestrates complex, multi-step PA workflows, ensuring all necessary documentation aligns with NCCN guidelines and payer-specific criteria, thereby accelerating approval times and reducing administrative burden.